Professional Special Situation Investor, TripleS Special Situation Investing

Triple S Special Situations Investing

Professional Special Situation Investor

TripleS Special Situation Investing

Professional Special Situation Investor with over 20 years of experience.

Equity Bottom-Up

SpringWorks Therapeutics Inc / Equity Bottom-Up

<ul><li>SpringWorks Therapeutics represents a highly attractive risk-reward opportunity with substantial upside potential from an imminent acquisition.</li><li>The company is currently in play with confirmed acquisition talks and multiple signs pointing to a transaction at a significant premium to current levels.</li><li><strong>Current price:</strong> $50, <strong>Target price: </strong>$70-85, representing approximately 50% upside with limited downside risk.</li></ul>

SpringWorks Therapeutics represents a highly attractive risk-reward opportunity with substantial upside potential from an imminent acquisition.The company is currently in play with confirmed acquisition talks and multiple signs pointing to a transaction at a significant premium to current levels.Current price: $50, Target price: $70-85, representing approximately 50% upside with limited downside risk.

SpringWorks Therapeutics (SWTX): A Compelling Biotech Buyout Thesis with Limited Downside

United States

SpringWorks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company acquires, develops, and commercializes medicines for patients suffering various diseases and cancer. SpringWorks Therapeutics serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00